Member Info for inanaco

try a Peli ... they are really good .. even got decompression valves

what case stronger ? you don't have one

waiting results

https://www.proactiveinvestors.co.uk/companies/news/202553/scancell-holdings-extends-collaboration-with-sweden-s-karolinska-institute-202553.html

Update on phase III clinical trial of investigational MAGE-A3 antigen-specific cancer immunotherapeutic in non-small cell lung cancer
GSK announced its decision to stop the MAGRITi trial, a Phase III trial of its MAGE-A3ii cancer immunotherapeuticiii in non-small cell lung cancer (NSCLC) patients, after establishing that it will not be possible to identify a sub-population of gene-signature positive NSCLC patients that may benefit from the treatment.

oh look at this ........... same "format as oxford"

French biotech Transgene has ceased the development of a therapeutic cancer vaccine that failed to shrink tumors in patients with lung cancer in a phase II trial.

In the phase II trial, Transgene tested its therapeutic cancer vaccine in combination with chemotherapy and the checkpoint inhibitor drug nivolumab, marketed as Opdivo. The treatment failed to significantly shrink the tumors of 40 patients suffering from non-small cell lung cancer. As a consequence, the company has decided to abandon the vaccine’s development, which was being carried out in collaboration with the big pharma Bristol-Myers Squibb.

The cancer vaccine candidate consists of a modified vaccinia virus that carries the genetic instructions to produce two proteins that boost the response of the immune system against cancer.

This phase II failure is the second major setback for Transgene in the last six months. In August, Transgene decided to abandon the development of a virus-based therapy designed to hunt down and kill cancer cells after interim analyses in a phase III trial concluded that it would be futile.

Transgene’s stock price has sunk by more than 18% on Euronext Paris since the announcement. The company will now focus on developing next-generation oncolytic virus treatments, with one of the most advanced treatments in an ongoing phase I/II trial expected to finish late 2020.

why can't they do it ???
money .... no problem
staff resource ... no problem

lets try another question

Name one melanoma vaccine that has been approved ..... ?

name one "Big Pharma" that has developed a melanoma vaccine .... ?

here is another "personalized vaccine" ...

https://www.ajmc.com/newsroom/personalized-cancer-vaccine-yields-promising-results-for-patients-with-highrisk-melanoma

better still why dont we look at ...

What other compounds got a better response than SCIB1 ..... ?

this one ?

https://www.fiercebiotech.com/biotech/roche-biontech-post-low-response-rate-cancer-vaccine-trial

Just like SCIB1 ... it has restrictions for use .. HLA you may of seen this with moditope as well ... so the vaccine sCIB1 will work in 45% of patients, in SCIB2 which is a more advanced immunobody this increases to 90% which matches moditope 90% ... so Scancell i suggest are trying to encompass as many HLA types as possible ..

https://en.wikipedia.org/wiki/Human_leukocyte_antigen

While the details of the clinical picture of the COVID-19 pandemic continue to emerge, there remain substantial unanswered questions regarding the role of individual genetic variability in the immune response against SARS-CoV-2 (51). We hypothesize that individual HLA genotypes may differentially induce the T-cell mediated antiviral response and could potentially alter the course of disease and its transmission. In this study, we performed a comprehensive in silico analysis of viral peptide-major histocompatibility complex (MHC) class I binding affinity across 145 different HLA types for the entire SARS-CoV-2 proteome.

https://jvi.asm.org/content/94/13/e00510-20

Scancell is adding peptides ... to the immunobody construct as its well capable of carrying at least 16 ....

Regarding SARS-CoV-2 CD8+ T cell responses, the pattern of immunodominance found here differed from the literature for other coronaviruses. However, stringent comparisons are not possible, as some earlier studies were not similarly comprehensive and did not utilize the same experimental strategy. The spike protein was a target of human SARS-CoV-2 CD8+ T cell responses, but it is not dominant. SARS-CoV-2 M was just as strongly recognized, and significant reactivity was noted for other antigens, mostly nsp6, ORF3a, and N, which comprised nearly 50% of the total CD8+ T cell response, on average. Thus, these data indicate that candidate COVID-19 vaccines endeavoring to elicit CD8+ T cell responses against the spike protein will be eliciting a relatively narrow CD8+ T cell response compared to the natural CD8+ T cell response observed in mild to moderate COVID-19 disease. An optimal vaccine CD8+ T cell response to SARS-CoV-2 might benefit from additional class I epitopes, such as the ones derived from the M, nsp6, ORF3a, and/or N.

https://www.sciencedirect.com/science/article/pii/S0092867420306103?via%3Dihub

thanks for the conformation Nom ...

Non Shareholder use "They"

shareholders use "We"

its the small things that let people down ..

another example ...

that SCLP has a really good Portfolio

using SCLP creates distance ...

""so we have a really good portfolio ..."" = part of it .. a shareholder

it changes ...

hence indicative ..

that is an indicative value ... generated by Algo's .. ... they also contain error

actual is 6.3 last buy

you are out of tolerance already ..............

Konar ...

but in fairness to you chap .......... your are not a statistics and probabilities expert and have never claimed to be ...

difference here is ... Ruck has

which begs the question how on earth can he question others "predictions" ... if the base algo he is using has the potential of unknown errors

how does these unknown errors translate to Risk ... a 10% error is an enormous margin ...

maybe he should put .............. £10 a share plus or minus 10% so in this instance the of 10% of the value = £1

so Ruck should be £10 plus or minus £1 ... that then allows for "proven" error ...

a bit of Fun ...

please don't take it to serious ...

I think it was Knowlesi buying in ...

Ruck ... but its your actual Job ??

writing software for probabilities ... algo's .. statistics ...

my job is not designing vaccines or deciphering research papers ... its just a hobby ...